2014年
Impact of early use of lenalidomide and low-dose dexamethasone on clinical outcomes in patients with relapsed/refractory multiple myeloma
International Journal of Hematology
- 巻
- 101
- 号
- 1
- 開始ページ
- 37
- 終了ページ
- 45
- 記述言語
- 掲載種別
- 研究論文(学術雑誌)
- DOI
- 10.1007/s12185-014-1696-6
© 2014, The Japanese Society of Hematology. We retrospectively investigated the prognostic factor of lenalidomide plus low-dose dexamethasone (Rd) in Japanese patients with refractory or relapsed multiple myeloma (RRMM) registered in the Kansai Myeloma Forum from January 2006 to December 2013. A total of 140 patients were analyzed. The median age was 66 years. The overall response rate was 68.6 %, including 33.1 % with a better than very good partial response. At 13.0 months median follow-up, the median overall survival (OS) and progression-free survival (PFS) were 34.2 and 17.0 months, respectively. In univariate analyses, patients with one or two prior therapies had significantly longer OS (41.2 vs. 21.5 months; P = 0.002) and PFS (29.0 vs. 13.0 months; P = 0.006) than patients treated with three or more prior therapies. Prior use of thalidomide was associated with significantly shorter PFS (19.0 vs. 16.0 months; P = 0.045). The prior use of bortezomib or high-dose therapy with stem cell transplantation, and the International Staging System had no impact on long-term outcome. Multivariate analysis showed that only the number of prior therapies was a significant predictor of both OS and PFS. Our findings suggest that greater benefit may occur when Rd therapy is used at the first or second relapse in RRMM.
- リンク情報
- ID情報
-
- DOI : 10.1007/s12185-014-1696-6
- ISSN : 0925-5710
- eISSN : 1865-3774
- PubMed ID : 25385278
- SCOPUS ID : 84922074292